PubRank

Jordan J Feld

Author PubWeight™ 58.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012 7.62
2 Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010 2.61
3 Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2009 2.41
4 Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011 2.33
5 A Canadian screening program for hepatitis C: is now the time? CMAJ 2013 2.33
6 Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2010 2.28
7 American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010 1.91
8 Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis. J Clin Oncol 2012 1.90
9 An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015 1.86
10 Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013 1.77
11 Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010 1.70
12 Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology 2013 1.63
13 Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2013 1.63
14 Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010 1.58
15 An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012 1.57
16 Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology 2014 1.52
17 Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2006 1.47
18 Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients. Pediatr Infect Dis J 2009 1.40
19 Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2011 1.32
20 Viral hepatitis and HIV in Africa. AIDS Rev 2007 1.27
21 Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012 1.16
22 Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology 2007 1.10
23 Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clin Gastroenterol Hepatol 2009 1.02
24 Influence of socioeconomic status on survival of hepatocellular carcinoma in the Ontario population; a population-based study, 1990-2009. PLoS One 2012 1.02
25 Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 2006 0.99
26 The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol 2013 0.96
27 HCV persistence: cure is still a four letter word. Hepatology 2005 0.90
28 Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008 0.90
29 How does coffee prevent liver fibrosis? Biological plausibility for recent epidemiological observations. Hepatology 2014 0.89
30  Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Ann Hepatol 2012 0.89
31 Virological responses during treatment for recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV co-infection. AIDS 2012 0.84
32 Protein interferon-stimulated gene 15 conjugation delays but does not overcome coronavirus proliferation in a model of fulminant hepatitis. J Virol 2014 0.83
33 The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. Can J Gastroenterol Hepatol 2014 0.82
34 Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma? Semin Liver Dis 2013 0.81
35 Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med 2016 0.79
36 Editorial commentary: sustained virologic response for patients with hepatitis C-related cirrhosis: a major milestone, but not quite a cure. Clin Infect Dis 2013 0.78
37 Interferon responses and spontaneous HCV clearance: is it all a matter of fat? J Hepatol 2012 0.78
38 Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat 2015 0.78
39 Liver stiffness increases acutely during sickle cell vaso-occlusive crisis. Am J Hematol 2013 0.77
40 Evolution of therapy for chronic hepatitis B: progressing from the simple to the complex. Ann Intern Med 2007 0.77
41 Management of HCV in cirrhosis-a rapidly evolving landscape. Curr Gastroenterol Rep 2015 0.76
42 Acute hepatitis C: management in the rapidly evolving world of HCV. Curr Gastroenterol Rep 2014 0.76
43 Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. Curr Opin Rheumatol 2014 0.75
44 Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2015 0.75